KNIGHT THERAPEUTICS INC (GUD.CA) Stock Price, Quote, News and Overview
TSX:GUD - Toronto Stock Exchange - CA4990531069 - Common Stock - Currency: CAD
GUD.CA Quote, Performance and Key Statistics
TSX:GUD (6/13/2025, 7:00:00 PM)
6.03
-0.06 (-0.99%)
The current stock price of GUD.CA is 6.03 CAD. In the past month the price increased by 3.25%. In the past year, price increased by 5.79%.
GUD.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.58 | 3.00B | ||
| CRON.CA | CRONOS GROUP INC | 14.61 | 1.01B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 6.26 | 750.61M | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 574.30M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 4.27 | 512.42M | ||
| ACB.CA | AURORA CANNABIS INC | 34.7 | 437.78M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 428.67M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 26.71 | 335.37M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 268.94M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | 31.67 | 254.37M | ||
| HITI.CA | HIGH TIDE INC | N/A | 251.22M | ||
| CRDL.CA | CARDIOL THERAPEUTICS INC-A | N/A | 163.57M |
Related stock screener links
About GUD.CA
Company Profile
Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The company is headquartered in Montreal, Quebec and currently employs 745 full-time employees. The company went IPO on 2014-02-28. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The company finances other life sciences companies and secures product distribution rights for Canada and select international markets. The firm invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. The company develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
Company Info
KNIGHT THERAPEUTICS INC
3400 De Maisonneuve Blvd W
MONTREAL QUEBEC H3Z 3B8 CA
CEO: Jonathan Ross Goodman
Employees: 745
Phone: 15144844483
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
What is the stock price of KNIGHT THERAPEUTICS INC today?
The current stock price of GUD.CA is 6.03 CAD. The price decreased by -0.99% in the last trading session.
What is the ticker symbol for KNIGHT THERAPEUTICS INC stock?
The exchange symbol of KNIGHT THERAPEUTICS INC is GUD and it is listed on the Toronto Stock Exchange exchange.
On which exchange is GUD.CA stock listed?
GUD.CA stock is listed on the Toronto Stock Exchange exchange.
What is the price forecast or stock price prediction for KNIGHT THERAPEUTICS INC stock?
11 analysts have analysed GUD.CA and the average price target is 7.71 CAD. This implies a price increase of 27.83% is expected in the next year compared to the current price of 6.03. Check the KNIGHT THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KNIGHT THERAPEUTICS INC worth?
KNIGHT THERAPEUTICS INC (GUD.CA) has a market capitalization of 600.77M CAD. This makes GUD.CA a Small Cap stock.
How many employees does KNIGHT THERAPEUTICS INC have?
KNIGHT THERAPEUTICS INC (GUD.CA) currently has 745 employees.
What are the support and resistance levels for KNIGHT THERAPEUTICS INC (GUD.CA) stock?
KNIGHT THERAPEUTICS INC (GUD.CA) has a support level at 5.96 and a resistance level at 6.11. Check the full technical report for a detailed analysis of GUD.CA support and resistance levels.
Is KNIGHT THERAPEUTICS INC (GUD.CA) expected to grow?
The Revenue of KNIGHT THERAPEUTICS INC (GUD.CA) is expected to grow by 9.9% in the next year. Check the estimates tab for more information on the GUD.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy KNIGHT THERAPEUTICS INC (GUD.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GUD.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GUD.CA, evaluating the profitability, health, valuation and growth aspects
- KNIGHT THERAPEUTICS INC (GUD.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KNIGHT THERAPEUTICS INC (GUD.CA) Sales and EPS estimates to see what analysts future expectations are.
- KNIGHT THERAPEUTICS INC (GUD.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KNIGHT THERAPEUTICS INC (GUD.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- KNIGHT THERAPEUTICS INC (GUD.CA) Stock Chart to make your own analysis
- KNIGHT THERAPEUTICS INC (GUD.CA) Latest news and press-releases to stay up to date.
Does KNIGHT THERAPEUTICS INC (GUD.CA) stock pay dividends?
GUD.CA does not pay a dividend.
When does KNIGHT THERAPEUTICS INC (GUD.CA) report earnings?
KNIGHT THERAPEUTICS INC (GUD.CA) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of KNIGHT THERAPEUTICS INC (GUD.CA)?
The PE ratio for KNIGHT THERAPEUTICS INC (GUD.CA) is 54.82. This is based on the reported non-GAAP earnings per share of 0.11 and the current share price of 6.03 CAD. Check the full fundamental report for a full analysis of the valuation metrics for GUD.CA.
GUD.CA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to GUD.CA. When comparing the yearly performance of all stocks, GUD.CA turns out to be only a medium performer in the overall market: it outperformed 44.15% of all stocks.
GUD.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GUD.CA. While GUD.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
GUD.CA Financial Highlights
Over the last trailing twelve months GUD.CA reported a non-GAAP Earnings per Share(EPS) of 0.11. The EPS increased by 168.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.97% | ||
| ROA | 1.1% | ||
| ROE | 1.39% | ||
| Debt/Equity | 0.04 |
GUD.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to GUD.CA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 13.52% and a revenue growth 9.9% for GUD.CA